Prof. Dollar schreef op 23 februari 2019 12:26:
[...]
Hi Yvonne!
Please contact Daniel Leonard. He is the Director of Global Patient Advocacy at uniQure. You can contact him via Patients@uniQure.com
Furthermore, try to follow the news regarding AMT-130 for Huntington’s Disease (HD). AMT-130 uses the Company’s proprietary uniQURE™ silencing technology that will also be used in AMT-150. The company expects that this year AMT-130 will be the first one-time administered AAV gene therapy to enter clinical testing for the treatment of Huntington’s disease.
Best,
Prof. Dollar
twitter.com/Prof_Dollar